[12] Patent
[11] Patent No.:GC0011444  
[45] Date of Publishing the Grant of the Patent: 31/Oct /2020                75/2020  
Number of the Decision to Grant the Patent:2020/173914
Date of the Decision to Grant the Patent:12/Oct/2020

[21] Application No.:GC 2012-21175

[22] Filing Date:2/5/2012

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
US
US
12/1/2012
24/10/2011
2/5/2011
61/585.859
61/550.545
61/481.533

[72] Inventors:1- Irving H Fox،2- Catherine Scholz،3- Csanad M. Varga،4- Vaithianathan Palaniappan،5- Jason Brown،6- Willow Diluzio،7- Nobel T. Truong

[73] Owner: Millennium Pharmaceuticals, Inc., USA

[74] Agent: Suleiman I. Al-Ammar Law Office

  

 

  

[51]IPC:
A61P1/00 A61K39/395 C07K16/28

[56] Cited Documents:

-CLELAND J L ET AL: A SPECIFIC MOLAR RATIO OF STABILIZER TO PROTEIN IS REQUIRED
FOR STORAGE STABILITY OF A LYOPHILIZED MONOCLONAL ANTIBODY,
JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION,
WASHINGTON, US, vol. 90, no. 3, 1 March 2001 (2001-03-01), pages 310-321, XP001179875,
-WO 0178779 A2 (MILLENNIUM PHARM INC [US]; GENENTECH INC [US]; BRETTMAN LEE R [US]; FO) 25 October 2001
-US 2007122404 A1 (O'KEEFE THERESA L [US]) 31 May 2007
-WO 9806248 A2 (LEUKOSITE INC [US]) 19 February 1998
 
Examiner: PH. Neda J. AlMuallem

[54] FORMULATION FOR ANTI-I+-4I7 ANTIBODY
[57] Abstract: Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-?4?7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-?4?7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.
No. of claims: 42     No. of figures: 10


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.